AcquisitionOther
Gilead Sciences, Inc. acquired Arcellx
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Gilead Sciences, Inc. -> Arcellx · $7.8 billion
Acquires full control of anito-cel CAR T-cell therapy, accelerating development and commercialization while eliminating profit-share arrangements.
Open source record (SEC) ↗